Premium Nahrungsergänzungsmittel | artgerecht

CAR-T Cell Therapy: How It Works, Uses & Side Effects

CAR-T cell therapy is an innovative immunotherapy in which a patient's own T-cells are genetically engineered to specifically recognize and destroy cancer cells.

Regular tips about health Regular tips about health

Things worth knowing about "CAR-T cell therapy"

CAR-T cell therapy is an innovative immunotherapy in which a patient's own T-cells are genetically engineered to specifically recognize and destroy cancer cells.

What is CAR-T Cell Therapy?

CAR-T cell therapy (Chimeric Antigen Receptor T-Cell Therapy) is an advanced form of immunotherapy used to treat certain types of cancer. A patient's own T-cells – a specialized type of white blood cell that is part of the immune system – are collected, genetically modified in a laboratory, and then reinfused into the patient. The modified T-cells carry an artificially constructed receptor called the chimeric antigen receptor (CAR), which enables them to recognize and destroy cancer cells with high precision.

Mechanism of Action

The mechanism of CAR-T cell therapy is based on the targeted genetic reprogramming of T-lymphocytes. The key steps are:

Collection: T-cells are harvested from the patient through a process called leukapheresis (a blood cell separation procedure).
Genetic Engineering: In the laboratory, a viral vector is used to insert the genetic instructions for the CAR into the T-cells.
Expansion: The modified T-cells are multiplied in the laboratory to produce millions of cells.
Infusion: The CAR-T cells are returned to the patient via intravenous infusion.
Effect: Once inside the body, the CAR-T cells recognize specific proteins (antigens) on the surface of cancer cells and attack them directly.

Indications

CAR-T cell therapy is currently approved primarily for certain hematological (blood-related) cancers where conventional therapies have not been sufficiently effective. The main approved indications include:

Acute lymphoblastic leukemia (ALL) in children and young adults
Diffuse large B-cell lymphoma (DLBCL)
Multiple myeloma
Follicular lymphoma
Mantle cell lymphoma

Research into further applications, including solid tumors such as lung and colorectal cancer, is actively ongoing.

Treatment Process

CAR-T cell treatment is a multi-step process that can take several weeks to complete:

Patient Selection and Preparation: Not every patient is eligible. A thorough diagnosis and assessment of overall health is required.
Leukapheresis: T-cells are collected using a specialized blood separation machine over the course of several hours.
Manufacturing: Genetic modification and cell expansion typically takes 2 to 4 weeks and is carried out in specialized facilities.
Lymphodepleting Chemotherapy: Shortly before the infusion, the patient receives chemotherapy to suppress the immune system and create space for the CAR-T cells.
CAR-T Cell Infusion: The modified cells are administered intravenously.
Monitoring: The patient is closely monitored as serious side effects can occur.

Side Effects

CAR-T cell therapy can cause severe side effects that require intensive medical supervision:

Cytokine Release Syndrome (CRS): A strong immune response that can cause fever, low blood pressure, organ dysfunction, and in severe cases life-threatening complications.
ICANS (Immune Effector Cell-Associated Neurotoxicity Syndrome): Neurological symptoms such as confusion, speech difficulties, or impaired consciousness.
B-cell Aplasia: A lasting deficiency of healthy B-cells, increasing susceptibility to infections.
Infections: A weakened immune system significantly increases the risk of infection.
Tumor Lysis Syndrome: Massive release of cellular breakdown products resulting from rapid cancer cell destruction.

Opportunities and Limitations

CAR-T cell therapy has achieved remarkable remission rates in certain patients with advanced or relapsed cancers, including durable complete remissions in some cases. However, significant challenges remain:

High cost of the therapy (often several hundred thousand euros or dollars)
Only available at specialized treatment centers
Not all patients respond to treatment
Relapses are possible if cancer cells lose or alter the targeted antigen
Currently limited efficacy against solid tumors

References

Maude SL et al. - Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. New England Journal of Medicine, 2018.
European Medicines Agency (EMA) - Authorization information for CAR-T cell therapies (Kymriah, Yescarta, Tecartus, etc.), as of 2023. Available at: www.ema.europa.eu
National Cancer Institute (NCI) - CAR T Cells: Engineering Patients' Immune Cells to Treat Their Cancers, 2022. Available at: www.cancer.gov

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.